Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose omalizumab in antihistamine-refractory chronic spontaneous urticaria
IRCT20250707066393N1Phase 4Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Urticaria Control Test questionnaire score. Started Jul 2025; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on IRCT20250707066393N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250707066393N1.